ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cancer

Trump Chooses Gottlieb to Run FDA; Pharma Breathes Sigh of Relief

Toni Clarke  |  March 13, 2017

WASHINGTON (Reuters)—U.S. President Donald Trump has chosen Dr. Scott Gottlieb, a conservative health policy expert with deep ties to the pharmaceutical industry, to lead the U.S. Food and Drug Administration, the White House said on Friday. If confirmed by the Senate, Gottlieb would be in charge of implementing Trump’s plan to dramatically cut regulations governing…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:FDAFood and Drug AdministrationTrump administration

As Biosimilars Hit, EU Pharma Warns against Blanket Prescribing

Reuters Staff  |  March 10, 2017

LONDON (Reuters)—European drugmakers, faced with increasing competition from cut-price copies of complex biotech drugs, cautioned doctors on Thursday to take care when switching patients from an established product to biosimilar version. The complex nature of biological medicines, which are made inside living cells, means copies can never be exactly the same as the original. But…

Filed under:Biologics/DMARDs Tagged with:biosimilar cancer drugBiosimilarsCancerTruxima

Moderate Alcohol Intake Decreases SLE Risk in Women

Arthritis Care & Research  |  March 8, 2017

Beer, wine, liquor—alcohol contains elements that suppress systemic inflammation, and its consumption has been linked to reduced risk of cardiovascular disease and RA. A recent analysis examined the effect of alcohol on SLE risk in women from the two Nurses’ Health Study cohorts. The results: Researchers found an inverse association between moderate alcohol consumption and SLE risk—with a 39% reduction in SLE risk among women who consumed about half a drink of alcohol daily…

Filed under:ConditionsSystemic Lupus Erythematosus

Baricitinib May Exhibit Better Efficacy Than Adalimumab for RA

Michele B. Kaufman, PharmD, BCGP  |  March 7, 2017

In a recent study, baricitinib proved more effective than adalimumab in treating adults with RA through 52 weeks…

Filed under:Drug Updates Tagged with:baricitinibRheumatoid Arthritis (RA)

Diagnosed by Artificial Intelligence?

Simon M. Helfgott, MD  |  February 16, 2017

“To err is human.” —Alexander Pope (1688–1744) The Wisest Minds in Medicine At some point during our careers, we have the privilege of meeting a physician so talented that everyone else pales in comparison. These are those gifted clinicians whose astonishing mastery of medicine makes everyone in their midst feel like inept, babbling fools. They…

Filed under:President's Perspective Tagged with:artificial intelligenceclinicianDiagnosismindpatient carePractice ManagementrheumatologistrheumatologyskillTreatmentWatson

Anti-Interleukin-6 Therapy for Erdheim-Chester Disease Warrants Study

Stefanie D. Wade, MD, Michael A. Seidman, MD, Edward C. Jones, MD, Arnold Radu, MD, Ryan Paterson, MD, Vikram Deshpande, MD, John H. Stone, MD, & Mollie N. Carruthers, MD  |  February 16, 2017

Erdheim-Chester disease (ECD) is a rare, non-Langerhan’s cell histiocytosis characterized by tissue infiltration of CD68-positive and CD1a-negative foamy histiocytes.1 ECD was discovered as a lipid granulomatosis in 1930 by Jakob Erdheim and his pupil, William Chester, and approximately 500 cases have been described to date.1 ECD has a heterogeneous course and prognosis ranging from an…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:anti-interleukincase reportClinicalDiagnosisDiseaseErdheim-ChesterinflammatoryinterferonPathogenesistherapyTreatment

U.S. Healthcare Costs to Escalate Over Next Decade

Reuters Staff  |  February 16, 2017

WASHINGTON—The cost of medical care in the United States is expected to grow at a faster clip over the next decade and overall health spending growth will outpace that of the gross domestic product, a U.S. government health agency said on Wednesday. A report by the U.S. Centers for Medicare and Medicaid Services (CMS) cited…

Filed under:Professional Topics Tagged with:Affordable Care Act (ACA)healthcare costU.S. Centers for Medicare and Medicaid Services (CMS)

Baricitinib Effective for Treating Refractory Rheumatoid Arthritis

Mary Beth Nierengarten  |  February 15, 2017

Soon, rheumatologists may have another drug to offer their patients with refractory rheumatoid arthritis (RRA) for whom effective and safe treatment remains challenging. A study published in the New England Journal of Medicine shows that patients with RRA treated with once-daily baricitinib in a 4 mg dose had a significant clinical improvement in symptoms of…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:adverse eventsbaricitinibClinicaldrugoutcomepatient carerefractory rheumatoid arthritisResearchrheumatologystudyTreatmenttrial

Syda Productions/shutterstock.com

Tips, Resources to Help Rheumatologists Educate Patients on Biologics and Biosimilars

Vanessa Caceres  |  February 15, 2017

Rheumatologists are accustomed to educating patients about medications—but biologic medications require some additional time and discussion. “Biologics are inherently more complex [than other medications], and there are multiple issues to consider before initiating treatment,” says K. “Kwas” Huston, MD, The Center for Rheumatic Disease, Kansas City, Mo. “This includes the patient’s disease activity, prior medications…

Filed under:Biologics/DMARDsDrug UpdatesPractice Support Tagged with:Association of Rheumatology Professionals (ARP)BiologicsDrugspatient carePractice ManagementQualityrheumatologistrheumatologySafetytherapyTreatment

Denosumab Does Not Increase Risk of Infection in RA Patients

Lara C. Pullen, PhD  |  February 13, 2017

New research dispels the fear that denosumab will increase the risk of infection in vulnerable populations with rheumatoid arthritis when it is prescribed in combination with TNF inhibitors or other biologics. Investigators found the treatment did not increase infection risk beyond what is expected for the patients’ disease, comorbidities and medications…

Filed under:ConditionsOsteoarthritis and Bone DisordersRheumatoid Arthritis Tagged with:2016 ACR/ARHP Annual MeetingACR/ARHP Annual MeetingdenosumabInfectionOsteoporosisRheumatoid Arthritis (RA)

  • « Previous Page
  • 1
  • …
  • 49
  • 50
  • 51
  • 52
  • 53
  • …
  • 86
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences